Toon van der Gronde

Osimertinib after Chemoradiotherapy in Stage III <i>EGFR</i> -Mutated NSCLC

Shun Lu, Terufumi Kato, Xiaorong Dong et al. · New England Journal of Medicine · 2024 · 232 citations

Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2–IA3 EGFR-Mutated NSCLC: ADAURA2

Yasuhiro Tsutani, Jonathan W. Goldman, Yasushi Yatabe et al. · Clinical Lung Cancer · 2023 · 64 citations · Full text

Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non–small-cell Lung Cancer: LAURA Trial in Progress

Shun Lü, Ignacio Casarini, Terufumi Kato et al. · Clinical Lung Cancer · 2021 · 63 citations

Definitive Chemoradiation, Medicine, Osimertinib Maintenance +9

Plasma Epstein-Barr virus DNA for pediatric Burkitt lymphoma diagnosis, prognosis and response assessment in Malawi

Katherine D. Westmoreland, Nathan D. Montgomery, Christopher C. Stanley et al. · International Journal of Cancer · 2017 · 48 citations · Full text

Translation, psychometric validation, and baseline results of the Patient‐Reported Outcomes Measurement Information System (PROMIS) pediatric measures to assess health‐related quality of life of patients with pediatric lymphoma in Malawi

Katherine D. Westmoreland, Bryce B. Reeve, Amy Amuquandoh et al. · Pediatric Blood & Cancer · 2018 · 35 citations